Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Valeant

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

J&J’s one-dose COVID-19 vaccine granted EU authorisation

Company aiming to begin vaccine delivery to EU in the second half of April

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

- PMLiVE

J&J’s one-dose COVID-19 vaccine granted emergency use approval by FDA

Company has already started shipping doses of the vaccine to the US

- PMLiVE

FDA briefing document backs J&J’s one-dose COVID-19 vaccine

Company is seeking an emergency use authorisation in the US

- PMLiVE

J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing

In phase 3, J&J's vaccine was 66% effective overall at preventing moderate-to-severe COVID-19

- PMLiVE

UK hits ‘significant milestone’ as 15 million people receive their first COVID-19 vaccine dose

The NHS also announced that five additional large-scale vaccination centres will open this week

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

- PMLiVE

The Brexit clock is counting down and time is running out

What businesses need to know about post-Brexit immigration

- PMLiVE

J&J completes enrolment for late-stage COVID-19 vaccine trial

Company announces that around 45,000 participants have been enrolled

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links